CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America

MONMOUTH JUNCTION, N.J., Nov. 9, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announced that at last evening's awards ceremony, it ranked 7th amongst 21 medical device companies, and 297^th overall in any industry on Deloitte's 2017 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, healthcare and life sciences, and energy tech companies in North America.  The company's revenues grew by 293% in the three-year period from 2013 to 2016.

CytoSorbents' Chief Executive Officer, Dr. Phillip Chan, credits global demand for its patented CytoSorb® blood purification technology that helps control severe inflammation—alongside its direct sales force and a growing roster of independent distributors and strategic partners, including some of the world's leading healthcare companies—for its revenue growth.

"Severe, uncontrolled inflammation is deadly, particularly in critical illnesses like sepsis that kills someone in the world every 3 to 4 seconds despite the use of antibiotics," Dr. Chan said. "It is also the common thread contributing to organ failure and death in nearly one-third of patients with a wide range of life-threatening conditions such as severe trauma, burn injury, surgical complications, liver failure, lung failure, pancreatitis, cytokine release syndrome, and many others."

Dr. Chan continued, "Better therapies are needed to improve patient outcomes and to stem the massive costs of ICU care. By reducing excessive inflammatory toxins from a patient's bloodstream, our flagship product CytoSorb^® is helping to safely bring deadly inflammation under control, contributing to greater patient stability, less severe disease, and better clinical outcomes in these patients. CytoSorb^® is now distributed throughout most of the European Union, and in a total of 44 countries worldwide. As CytoSorbents drives to operating profitability, expected in 2018, it is also pursuing U.S. approval with the expected initiation of its pivotal, registration trial in complex cardiac surgery by the end of this year."

"The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment," said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. "These companies are on the cutting edge and are transforming the way we do business. We extend our sincere congratulations to all the winners for achieving remarkable growth while delivering new services and experiences for their customers."

"Emerging growth companies are powering innovation in the broader economy. The growth rates delivered by the companies on this year's North America Technology Fast 500 ranking are a bright spot for the capital markets and a strong indicator that the emerging growth technology sector will continue to deliver a strong return on investment," said Heather Gates, national managing director of Deloitte & Touche LLP's emerging growth company practice. "Deloitte is dedicated to supporting the best and brightest companies of the future in the emerging growth company sector. We are proud to acknowledge the significant accomplishments of this year's Fast 500 winners."

About Deloitte's 2017 Technology Fast 500™

For the past 23 years, Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2013 to 2016.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 44 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety and efficacy of free hemoglobin reduction with intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery.  In 2017, the Company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 27,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $21 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), and others.  The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, K⁺ontrol™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com, and follow us on Facebook and Twitter.

Forward-Looking Statements 
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

Please Click to Follow Us on Facebook and Twitter

CytoSorbents Contact:
Amy Vogel
Investor Relations
(732) 398-5394 
[email protected]

Investor Relations Contact:
Bob Yedi
LifeSci Advisors
646-597-6989 
[email protected]

Public Relations Contact:
Joshua Berkman
Rubenstein Public Relations
212-805-3055     
[email protected]

SOURCE CytoSorbents Corporation

Related Links

http://www.cytosorbents.com